Page 225 - SAHCS HIVMed Journal Vol 20 No 1 2019

Page 6 of 6 Original Research

4. Palella FJ, Jr, Baker RK, Moorman AC, et al. Mortality in the highly active 22. Kirk GD, Astemborski J, Mehta SH, et al. Assessment of liver fibrosis by transient
antiretroviral therapy era: Changing causes of death and disease in the HIV elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus
outpatient study. J Acquir Immune Defic Syndr. 2006;43(1):27–34. https://doi. coinfection. Clin Infect Dis. 2009;48(7):963–972. https://doi.org/10.1086/597350
org/10.1097/01.qai.0000233310.90484.16 23. Wai C, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both
5. Iroezindu MO, Agbaji OO, Daniyam CA, Isiguzo GC, Isichei C, Akanbi MO. Liver significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology.
function test abnormalities in Nigerian patients with Human Immunodeficiency 2003;38(2):518–526. https://doi.org/10.1053/jhep.2003.50346
Virus and hepatitis B virus co-infection. Int J STD AIDS. 2013;24(6):461–467. 24. Ngo Y, Munteanu M, Messous D, et al. A prospective analysis of the prognostic
https://doi.org/10.1177/0956462412473889 value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem.
6. Matthews GV, Neuhaus J, Bhagani S, et al. Baseline prevalence and predictors of 2006;52(10):1887–1896. https://doi.org/10.1373/clinchem.2006.070961
liver fibrosis among HIV-positive individuals: A substudy of the INSIGHT Strategic 25. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: An inexpensive and accurate
Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015;16(S1):129–136. marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest.
https://doi.org/10.1111/hiv.12241 Hepatology. 2007;46(1):32–36. https://doi.org/10.1002/hep.21669
7. Bataller RN, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115(2):209–218. https:// 26. Rockstroh JK, Mohr R, Behrens G, Spengler U. Liver fibrosis in HIV: Which role does
doi.org/10.1172/JCI24282 HIV itself, long-term drug toxicities and metabolic changes play? Curr Opin HIV
8. Baranova A, Lal P, Birerdinc A, Younossi ZM. Non-invasive markers for hepatic fibrosis. AIDS. 2014;9(4):365–370. https://doi.org/10.1097/COH.0000000000000064
BMC Gastroenterol. 2011;11(1):91. https://doi.org/10.1186/1471-230X-11-91 27. Scaradavou A. HIV-related thrombocytopenia. Blood Rev. 2002;16(1):73–76. https://
9. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B doi.org/10.1054/blre.2001.0188
or C. Gastroenterology. 2012;142(6):1293–1302. https://doi.org/10.1053/j.gastro. 28. Gitau SN, Vinayak S, Silaba M, Adam R, Shah R. High prevalence of liver fibrosis in
2012.02.017 patients with human immunodeficiency virus monoinfection and human
10. Liu T, Wang X, Karsdal MA, Leeming DJ, Genovese F. Molecular serum markers of immunodeficiency virus Hepatitis-B co-infection as assessed by shear wave
liver fibrosis. Biomark Insights. 2012;7:105–117. https://doi.org/10.4137/BMI. elastography: Study at a teaching hospital in Kenya. J Clin Imaging Sci. 2016;6:22.
S10009 https://doi.org/10.4103/2156-7514.183582
11. Sebastiani G, Vario A, Guido M, Alberti A. Sequential algorithms combining non- 29. DallaPiazza M, Amorosa VK, Localio R, Kostman JR, Re VL. Prevalence and risk
invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis factors for significant liver fibrosis among HIV-monoinfected patients. BMC Infect
B. World J Gastroenterol. 2007;13(4):525–531. https://doi.org/10.3748/wjg.v13. Dis. 2010;10(1):116. https://doi.org/10.1186/1471-2334-10-116
i4.525 30. Tahiri M, Sodqi M, Lahdami FEZ, et al. Risk factors for liver fibrosis among Human
12. Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of liver fibrosis: Clinical Immunodeficiency Virus monoinfected patients using the FIB4 index in Morocco.
World J Hepatol. 2013;5(10):584–588. https://doi.org/10.4254/wjh.v5.i10.584
translation of molecular pathogenesis or based on liver-dependent malfunction
tests. Clin Chim Acta. 2007;381(2):107–113. https://doi.org/10.1016/j.cca. 2007. 31. de Torres M, Poynard T. Risk factors for liver fibrosis progression in patients with
02.038 chronic hepatitis C. Ann Hepatol. 2003;2(1):5–11.
13. Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology. 32. Mendeni M, Focà E, Gotti D, et al. Evaluation of liver fibrosis: Concordance analysis
2006;43(S1):S113–S120. https://doi.org/10.1002/hep.21046 between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort
14. Fallatah HI. Noninvasive biomarkers of liver fibrosis: An overview. Adv Hepatol. of HIV-infected patients without hepatitis C and B infection. Clin Infect Dis.
2011;52(9):1164–1173. https://doi.org/10.1093/cid/cir071
2014;2014.
33. Paranaguá-Vezozzo DC, Andrade A, Mazo DF, et al. Concordance of non-invasive
15. Martin-Carbonero L, De Ledinghen V, Moreno A, et al. Liver fibrosis in patients mechanical and serum tests for liver fibrosis evaluation in chronic hepatitis
with chronic hepatitis C and persistently normal liver enzymes: Influence of HIV C. World J Hepatol. 2017;9(8):436–442. https://doi.org/10.4254/wjh.v9.i8.436
infection. J Viral Hepat. 2009;16(11):790–795. https://doi.org/10.1111/ j.1365-
2893.2009.01133.x 34. Atay K, Canbakan B, Alan O, et al. Evaluation of non-invasive diagnostic methods
16. Staabinski L, Reynolds SJ, Ocama P, et al. High prevalence of liver fibrosis as indicators of fibrosis in patients with nonalcoholic fatty liver disease. Biomed
Res. 2017;28(2):565–570.
associated with HIV infection: A cross-sectional study in rural Rakai, Uganda.
Antivir Ther. 2011;16(3):405–411. https://doi.org/10.3851/IMP1783 35. Park GJ, Lin BP, Ngu MC, Jones DB, Katelaris PH. Aspartate aminotransferase:
17. Amaral IdSA, Dias MPF, Fernandes CCR, Moia LdJMsP, Miranda ECBM, Demachki Alanine aminotransferase ratio in chronic hepatitis C infection: Is it a useful
predictor of cirrhosis? J Gastroenterol Hepatol. 2000;15(4):386–390. https://doi.
S. Evaluation of APRI test as a liver fibrosis marker. Rev Para Med. 2007;21(4): org/10.1046/j.1440-1746.2000.02172.x
7–13.
36. El Nakeeb NA, Helmy A, Saleh SA, Abdellah HM, Aleem MHA, Elshennawy D.
18. Poynard T, Morra R, Halfon P, et al. Meta-analyses of FibroTest diagnostic value in Comparison between FIB-4 Index and Fibroscan as marker of fibrosis in chronic
chronic liver disease. BMC Gastroenterol. 2007;7(1):40. https://doi.org/10.1186/1471- HCV infection in Egyptian patients. Open J Gastroenterol. 2014;4(12):383–391.
230X-7-40 https://doi.org/10.4236/ojgas.2014.412052
19. Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value 37. Grigorescu M, Rusu M, Neculoiu D, et al. The FibroTest value in discriminating
of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis between insignificant and significant fibrosis in chronic hepatitis C patients. The
(ActiTest) in patients with chronic hepatitis C. Comp Hepatol. 2004;3(1):8. https:// Romanian experience. J Gastrointestin Liver Dis. 2007;16(1):31–37.
doi.org/10.1186/1476-5926-3-8 38. Shaheen AA, Myers RP. Systematic review and meta-analysis of the diagnostic
20. Liu S, Schwarzinger Ml, Carrat F, Goldhaber-Fiebert JD. Cost effectiveness of accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection. HIV
fibrosis assessment prior to treatment for chronic hepatitis C patients. PLoS One. Clin Trials. 2008;9(1):43–51. https://doi.org/10.1310/hct0901-43
2011;6(12):e26783. https://doi.org/10.1371/journal.pone.0026783 39. Rossi E, Adams L, Prins A, et al. Validation of the FibroTest biochemical markers
21. Perazzo H, Veloso VG, Grinsztejn B, Hyde C, Castro R. Factors that could impact on score in assessing liver fibrosis in hepatitis C patients. Clin Chem. 2003;49(3):
liver fibrosis staging by transient elastography. Int J Hepatol. 2015;2015. 450–454. https://doi.org/10.1373/49.3.450

http://www.sajhivmed.org.za 218 Open Access